Clinical Trial: A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06922929) titled 'A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment' on April 03.

Brief Summary: A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in participants with suspected recurrent prostate cancer after radical treatment.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Prostate Cancer Recurrent

Intervention: DRUG: INR101

INR101 PET/ CT

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Yunhe Pharmaceutical (Tianjin)...